Gene Expression Profiling of Human Decidual Macrophages: Evidence for Immunosuppressive Phenotype

Charlotte Gustafsson1*, Jenny Mjöberg1, Andreas Matussek2, Robert Geffers3, Leif Matthiesen4, Göran Berg4, Surendra Sharma5,6, Jan Buer7, Jan Ernerudh1

1 Division of Clinical Immunology, Unit for Autoimmunity and Immune Regulation (AIR), Department of Clinical and Experimental Medicine, Faculty of Health Sciences, University Hospital, Linköping, Sweden, 2 Department of Clinical Microbiology, County Hospital Ryhov, Jönköping, Sweden, 3 Mucosal Immunity, Helmholtz Centre for Infection Research (HCI), Braunschweig, Germany, 4 Division of Gynecology and Obstetrics, Faculty of Health Sciences, University Hospital, Linköping, Sweden, 5 Department of Pediatrics, Brown University and Women and Infants’ Hospital of Rhode Island, Providence, Rhode Island, United States of America, 6 Department of Pathology, Brown University and Women and Infants’ Hospital of Rhode Island, Providence, Rhode Island, United States of America, 7 Institute of Medical Microbiology, University Hospital Essen, Essen, Germany

Abstract

Background: Although uterine macrophages are thought to play an important regulatory role at the maternal-fetal interface, their global gene expression profile is not known.

Methodology/Principal Findings: Using micro-array comprising approximately 14,000 genes, the gene expression pattern of human first trimester decidual CD14+ monocytes/macrophages was characterized and compared with the expression profile of the corresponding cells in blood. Some of the key findings were confirmed by real time PCR or by secreted protein. A unique gene expression pattern intrinsic of first trimester decidual CD14+ cells was demonstrated. A large number of regulated genes were functionally related to immunomodulation and tissue remodelling, corroborating polarization patterns of differentiated macrophages mainly of the alternatively activated M2 phenotype. These include known M2 markers such as CCL-18, CD209, insulin-like growth factor (IGF)-1, mannose receptor c type (MRC)-1 and fibronectin-1. Further, the selective up-regulation of triggering receptor expressed on myeloid cells (TREM)-2, alpha-2-macroglobulin (A2M) and prostaglandin D2 synthase (PGDS) provides new insights into the regulatory function of decidual macrophages in pregnancy that may have implications in pregnancy complications.

Conclusions/Significance: The molecular characterization of decidual macrophages presents a unique transcriptional profile replete with important components for fetal immunoprotection and provides several clues for further studies of these cells.

Introduction

A distinctive immune tolerance environment is programmed at the maternal-fetal interface to avoid rejection by the maternal immune system. The most abundant maternal immune cells in the deciduized endometrium are NK cells and macrophages. Although their exact roles are currently being debated, they are thought to regulate vascular growth and placenta development. Global gene expression profiling of decidual NK cells provided a unique pattern compared to their counterparts in blood [1]. In the case of monocytes/macrophages, accumulating data indicate that local environment drives them into functionally different subsets. Classically, macrophages activated by agents like IFN-γ, TNF or bacterial LPS, show profound effector functions like production of toxic intermediates, essential in the killing of intracellular microbes. They also secrete high amounts of pro-inflammatory and Th1 cytokines such as TNF and IL-12. On the other hand, macrophages activated by Th2 cytokines such as IL-4 and IL-13 as well as anti-inflammatory cytokine IL-10 induce a suppressive mode of activation and have been termed alternatively activated macrophages ([2], reviewed in [3,4]). In this regard, Mantovani et al [5] proposed a nomenclature where M1 and M2 represent inflammatory and anti-inflammatory cytokines, respectively. However, it is not clear whether decidual macrophages represent mainly M1 or M2 phenotype.

Due to their role in immune regulation, macrophages in the uterus are likely to contribute to local immune tolerance in normal pregnancy. They may do so by phagocytosis of apoptotic cells harbouring potentially pro-inflammatory and harmful effects on
Materials and Methods

Subjects

Decidual tissue and blood was obtained from eleven women between 18 and 41 years of age (median age 35 years) with normal pregnancies, undergoing elective surgical abortions in week 7 to 11 (median week 9) at the department of Gynecology and Obstetrics, Linköping University Hospital, Sweden. All pregnancies were between 18 and 41 years of age (median age 35 years) with normal pregnancies, undergoing elective surgical abortions in week 7 to 11 (median week 9) at the department of Gynecology and Obstetrics, Linköping University Hospital, Sweden. All pregnancies were detected viable and dated by crown-rump length measurement with ultrasound. Misoprostol (Cytotec®; Searle, USA) was given to the fetus (reviewed in [6]). Temporal expression of anti-inflammatory cytokines such as IL-4 [7–10], IL-13 [11–13] and IL-10 [7–10,14,15] is evident at the maternal-fetal interface, suggesting an environment capable of facilitating alternative activation of macrophages. It is thus likely that decidual macrophages reveal a suppressive or regulatory phenotype in the placenta [16,17] as well as in the decidua [9,18–21]. We report here, for the first time, a global gene expression pattern of decidual monocytes/macrophages. We compared them with the expression patterns of blood CD14 positive cells. A clearly distinct gene expression profile in decidual macrophages is evident, confirming a selective gene cascade regulation involved in immune modulation and tissue remodelling.

Isolation of CD14 positive cells and extraction of total RNA

Mononuclear cells were separated from decidua and blood as described previously [9]. CD14 positive cells were obtained by two different methods. Cells from five subjects were sorted by FACSAria cell sorting, a method resulting in high cell purity but with the possible disadvantage of causing high mechanical stress to the cells. Positive immunomagnetic MACS separation, a fast method with a relatively low physical impact on the cells, was performed in the six remaining subjects.

For immunomagnetic separation, CD14 positive cells were selected with anti-CD14 antibody coated beads (Miltenyi Biotec, Bergish Gladbach, Germany) according to the manufacturer’s instructions. Flow cytometry in 3 of 6 samples showed purity (% CD14+ cells) of 84, 88 and 92 in blood and 72, 74 and 76 in the decidua, respectively. For FACSAria (BD Bioscience) cell sorting, cells were labelled with anti-CD4FITC, CD14APC (Miltenyi Biotech), CD45PE-Cy5 and CD3 PE-Cy7 antibodies (BD Bioscience, Stockholm, Sweden). CD14 positive cells were defined as CD45−CD3−CD14+ cells and sorted accordingly. Purity of FACSAria sorted CD14 positive cells in the two subjects used for micro-array was 98.0 to 99.8% in blood and 96.2–97.2% in decidua, respectively. In the three subjects used for real-time PCR, purity was 93–98% in blood and 96–96% in the decidua, respectively. Following sorting, cells were lysed in RNasey RLT lysis buffer and total RNA was extracted according to the manufacturer’s instructions (Qiagen, West Sussex, UK).

Affymetrix GeneChip Assay

Samples were amplified for GeneChip analysis according to the recommended protocols by the manufacturer (Affymetrix, Santa Clara, CA, USA). In all cases, 10 µg of each biotinylated cRNA preparation was fragmented and placed in a hybridization cocktail containing four biotinylated hybridization controls (BioB, BioC, BioD, and Cre), as recommended by the manufacturer. Samples were hybridized to an identical lot of Affymetrix HG U133 2.0 GeneChips for 16 hours. After hybridization the GeneChips were washed, stained with SA-PE, and read using an Affymetrix GeneChip fluidic station and scanner.

Data Analysis

Analysis of micro-array data was performed using the Affymetrix GCOS 1.2 software. For normalization all array experiments were scaled to a target intensity of 150, otherwise using the default values of GCOS 1.2. Further downstream analysis was performed using Array Assist 4.0 (Stratagene, La Jolla, CA, USA). Data was normalized by the PLIER algorithm (Affymetrix, Santa Clara, CA, USA) using default parameters. Genes whose signal maximum intensity did not exceed 100 across all samples were excluded from further analysis. Student’s T-Test was applied to identify differences between decidual and blood monocytes/macrophaes. Genes whose p values were below or equal to 0.05 and mean fold changes more/less than +2/−2 fold in cells from two of the high purity FACSAria separated subjects were included in the analysis.

The methods performed on different subjects are shown in Table 1.

Table 1. Methods performed on the different subjects

| Subject | FACSAria sorting | MACS sorting | Micro-array | Real-time PCR | Protein detection | Flow cytometry* |
|---------|------------------|--------------|-------------|---------------|------------------|----------------|
| 1       | X                | X            | X           |                |                  | X              |
| 2       | X                | X            | X           |                |                  | X              |
| 3       | X                | X            | X           |                |                  | X              |
| 4       | X                | X            |             |                |                  | X              |
| 5       | X                | X            |             |                |                  | X              |
| 6       | X                | X            |             |                |                  | X              |
| 7       | X                | X            |             | X             | X                | X              |
| 8       | X                | X            |             | X             | X                | X              |
| 9       | X                | X            |             | X             |                  | X              |
| 10      | X                | X            | X           | X             |                  | X              |
| 11      | x                |              | X           | X             | X                |                |

*Flow cytometry for control of purity

doi:10.1371/journal.pone.0002078.t001
were considered differentially regulated in decidual samples compared with blood cells. These genes were used as a gene expression signature for the experiment, resulting in 408 regulated genes. Among these, genes fulfilling the same criteria in cells from the five MACS separated subjects were selected and resulted in the final 120 regulated genes. Alongside with these high-stringent requirements, data analysis with lower stringency was performed. With the requirement of two-fold increase/decrease and statistical difference in all seven subjects considered as a common group with no respect to the separation method used, a much higher number of genes were revealed regulated (n~1700). We chose to further analyse the genes obtained by the high-stringency requirements. These genes were grouped according to plausible functions in the context of macrophages in early pregnancy, resulting in the groups of genes encoding for proteins with immune regulatory material and a selection is summarized in Table 3. A major differentially regulated genes is provided as supplementary material (Table S1). The entire list of genes can be accessed using the GEO database (GSE10612; http://www.ncbi.nlm.nih.gov/projects/geo/). The microarray dataset is available at GEO database under Acc. No. GSE10612.

**Real-time PCR**

To confirm regulated genes in the micro-array, real-time PCR was performed on flow-cytometrically sorted CD14 positive cells obtained from three additional subjects. RNA was reversely transcribed with 500 U SuperScript II reverse transcriptase (Invitrogen, Carlsbad, California) according to the manufacturers protocol. Table 2 provides all genes with corresponding primers (synthesized by TIB Molbiol, Berlin, Germany) used for real-time PCR. Relative quantification was performed using the 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, California) under the following conditions: 10 min at 95°C followed by 40 cycles at 95°C for 13 seconds and 60 seconds at 60°C. Amplification of specific PCR products was detected using the SYBR Green PCR Master Mix (Applied Biosystems) in duplicates. The housekeeping ribosomal protein S9 (RPS9) gene was used for normalization. The number of genes analyzed was restricted by the low amount of lysate available.

**Analysis of ex vivo protein secretion from CD14 positive cells**

Blood and decidual immunomagnetically separated CD14 positive cells (50 000 cells) from five subjects were incubated over night in 200 μL of tissue culture medium (TCM) consisting of Iscoves modification of Dulbecco’s media (Gibco BRL, Paisley, Scotland) supplemented with (given as final concentrations in the medium): L-glutamine (Flow Laboratories, Irvine, Scotland) 292 mg/L; sodium bicarbonate 3.024 g/L; penicillin 50 IE/mL and streptomycin 50 μg/mL (Flow Laboratories) and 100 x non essential amino acids 10 mL/L (Flow Laboratories). The cell-free supernatants were stored at −70°C. The protein level of CCL18 was determined by an in-house double-antibody sandwich ELISA using a monoclonal anti-human CCL18 (0.5 μg/mL;clone 64507; R&D Systems, Abingdon, UK) and a polyclonal biotinylated anti-human CCL18 Antibody (200 ng/mL; R&D Systems). Streptavidin-poly-horse radish peroxidase and 3,3′,5,5′-tetramethylbenzidine liquid substrate (Sigma-Aldrich) were used for detection (Sandberg et al, unpublished results). The levels of CCL2 and matrix metalloproteinase 9 (MMP-9) in cell culture supernatants were analyzed according to the manufacturer’s instructions. The kits used were base kits LUFH000 and LMP000 together with analyte kits LUFH279 and LMP911 (all purchased from R&D Systems, Abingdon, UK). Protein concentrations were analyzed using the Luminex 100 instrument (Luminex Corporation, Austin, Texas, USA) and the STarStation software (v 2.3, Applied Cytometry Systems, Sheffield, UK). Genes were selected for protein analyses based on significance and possibility of detection due to availability of assay.

**Online supplemental material**

A complete table of the 120 differentially regulated genes is provided as supplementary material (Table S1). The entire microarray dataset is available at GEO database under Acc. No. GSE10612 (http://www.ncbi.nlm.nih.gov/projects/geo/).

**Results**

**Micro-array data**

Gene expression data revealed a total of 120 genes differently regulated (80 up-regulated and 40 down-regulated) in decidual CD14 positive cells compared to their blood counterparts, when using the most stringent statistical criteria. A complete list of differentially regulated genes is provided as supplementary material and a selection is summarized in Table 3. A major group of genes encode for proteins with immune regulatory functions. Further, genes associated with tissue remodelling, cell proliferation and cell metabolism were commonly regulated.

### Table 2. Primers used for real-time RT-PCR

| Product | 5’ Sequence 3’ | Funktion | Product length | Tm |
|---------|----------------|----------|----------------|-----|
| IDO     | ATT TGT CTG GCT GGA AAG GCA ACC | sense | 121 bp | 59,9 °C |
|         | AAG CAC TGA AAG ACG CTT TGG | antisense | 59,9 °C |
| TREM-2  | ACA ACT TGT GGC TGC TGT CCT T | sense | 122 bp | 57,3 °C |
|         | TTC CGC AGC GTA ATG GTG AGA GT | antisense | 59,5 °C |
| CD 209  | AAA TCA GGA AGG CAC GTG GCA ATG | sense | 86 bp | 59,9 °C |
|         | TGT TGG GCT CTC TCT TGG Att AAT | antisense | 59,9 °C |
| ICAM-3  | CAA TCT CAG CAA CTG GAG CCT CAA | sense | 90 bp | 59,9 °C |
|         | ACG GTG ATG TTA GAG GAG CCT GTT | antisense | 59,9 °C |
| NRP-1   | AAG ACC TTC TGC CAC TGG GAA CAT | sense | 103 bp | 59,9 °C |
|         | AGT TGC CAT CTC TCT GTG GAT CCT | antisense | 59,9 °C |
| RPS-9   | GGC GCA GAC GGT GGA AGC | sense | 83 bp | 59,6 °C |
|         | GGT CTC CAC GGG GTC ACA T | antisense | 60,0 °C |

Tm: melting temperature

DOI:10.1371/journal.pone.0002078.t002

---

**Table 2. Primers used for real-time RT-PCR**

| Product | 5’ Sequence 3’ | Funktion | Product length | Tm |
|---------|----------------|----------|----------------|-----|
| IDO     | ATT TGT CTG GCT GGA AAG GCA ACC | sense | 121 bp | 59,9 °C |
|         | AAG CAC TGA AAG ACG CTT TGG | antisense | 59,9 °C |
| TREM-2  | ACA ACT TGT GGC TGC TGT CCT T | sense | 122 bp | 57,3 °C |
|         | TTC CGC AGC GTA ATG GTG AGA GT | antisense | 59,5 °C |
| CD 209  | AAA TCA GGA AGG CAC GTG GCA ATG | sense | 86 bp | 59,9 °C |
|         | TGT TGG GCT CTC TCT TGG ATT AAT | antisense | 59,9 °C |
| ICAM-3  | CAA TCT CAG CAA CTG GAG CCT CAA | sense | 90 bp | 59,9 °C |
|         | ACG GTG ATG TTA GAG GAG CCT GTT | antisense | 59,9 °C |
| NRP-1   | AAG ACC TTC TGC CAC TGG GAA CAT | sense | 103 bp | 59,9 °C |
|         | AGT TGC CAT CTC TCT GTG GAT CCT | antisense | 59,9 °C |
| RPS-9   | GGC GCA GAC GGT GGA AGC | sense | 83 bp | 59,6 °C |
|         | GGT CTC CAC GGG GTC ACA T | antisense | 60,0 °C |
### Table 3. Selection of genes differentially expressed in decidual compared to blood CD14+ cells in early pregnancy.

| Gene name                                      | Gene bank accession number | Fold change a |
|------------------------------------------------|----------------------------|---------------|
| **Immune modulating**                          |                            |               |
| **Suppressive/Anti-inflammatory functions**    |                            |               |
| **Soluble form**                               |                            |               |
| Alpha-2-macroglobulin; A2M                     | NM_000014                  | 92            |
| V-set and immunoglobulin domain containing 4;VSIG4 | NM_007268                  | 23            |
| Prostaglandin D2 synthase, hematopoietic; PGDS | NM_014485                  | 13            |
| Chemokine (C-C motif) ligand 18;CCL18, AMAC1   | Y13710                     | 3.8           |
| **Membrane bound form**                        |                            |               |
| Mannose receptor, C type 1;MRC1                | NM_002438                  | 36            |
| CD209 antigen; DC-SIGN                        | AF290886                   | 16            |
| Triggering receptor expressed on myeloid cells 2;TREM2 | NM_018965                   | 9.0           |
| Tumor necrosis factor receptor superfamily, member 21; TNFRSF21 | NM_016629 | 7.3 |
| CD9 antigen (p24); CD9                        | NM_001769                  | 5.3           |
| Dipeptidase 2;DPEP2                            | NM_022355                  | −2.8          |
| C-type lectin domain family 4, member A;CLEC4A (LLIR) | AF200738                   | −3.0          |
| **Intracellular protein**                      |                            |               |
| Disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila); DAB2 | AF188298 | 30 |
| V-maf musculoskeletal fibrosarcoma oncogene homolog (avian); MAF | NM_005360 | 12 |
| Interleukin-1 receptor-associated kinase 3;IRAK3 | NM_007199 | −2.7 |
| **Activating/Pro-inflammatory functions**       |                            |               |
| **Soluble form**                               |                            |               |
| Secreted phosphoprotein; SPP1                  | M83248                     | 101           |
| Complement component 3;C3                      | NM_000064                  | 48            |
| Chemokine (C motif) ligand 2; XCL2             | U23772                     | 7.6           |
| Chemokine (C motif) ligand 2; CCL2, MCP1       | S69738                     | 5.8           |
| Chemokine (C motif) ligand 1; XCL1 (lymphotactin) | NM_003175                     | 5.7           |
| Chemokine (C motif) ligand 8;CCL8, MCP2        | A9084980                   | 5.0           |
| Proteolipid protein 2 (colonic epithelium-enriched);PLP2 | NM_002668 | −4.0 |
| S100 calcium binding protein A8 (calgranulin A);S100A8 | NM_002964 | −5.8 |
| Properdin P factor, complement;PFC            | NM_002621                  | −6.6          |
| **Membrane bound form**                        |                            |               |
| SLAM family member 8;SLAMF8                    | NM_020125                  | 4.7           |
| Bone marrow stromal cell antigen 1;BST1 (CD157) | NM_004334                  | −3.1          |
| Asialoglycoprotein receptor 2;ASGR2, CLEC4H2   | NM_001181                  | −4.1          |
| Intercellular adhesion molecule 3;ICAM3        | NM_002162                  | −4.8          |
| EGF-like-domain, multiple 5;EGFL5              | W68084                     | −5.9          |
| Selectin L (lymphocyte adhesion molecule 1);SELL | NM_00655                  | −7.0          |
| Vanin 2;VNN2                                   | NM_004665                  | −7.5          |
| **Tissue remodelling**                         |                            |               |
| Fibronectin 1;FN1                              | AF130095                   | 68            |
| Complement component 1, q subcomponent, beta polypeptide;C1QB | NM_000491 | 58 |
| Collagen, type III, alpha 1;COL3A1             | AU144167                   | 27            |
| Heat shock 27kDa protein 1; HSPB1              | NM_001540                  | 21            |
| Complement component 1, q subcomponent, alpha polypeptide;C1QA | NM_015991 | 16 |
| Endothelial PAS domain protein 1;EPAS1         | AF052094                   | 15            |
| Growth arrest-specific 6;GAP6                  | L13720                     | 11            |
| Collagen, type I, alpha 2;COL1A2               | AA788711                   | 10            |
| Collagen, type VI, alpha 3;COL6A3              | NM_004369                  | 9.9           |
| Collagen, type IV, alpha 2;COL4A2              | X05610                     | 9.3           |
| Serpin peptidase inhibitor, clade F, member 1;SERPINF1 | NM_002615 | 8.2 |
| Nerve growth factor receptor (TNFRSF16) associated protein 1;NGFRAP1 | NM_014380 | 7.9 |
| Matrix metalloproteinase 9;MMP9, plasminogen  | NM_004994                  | 6.5           |
| Gene name                                                                 | Gene bank accession number | Fold change* |
|--------------------------------------------------------------------------|----------------------------|--------------|
| Protein S (alpha); PROS1                                                  | NM_000313                  | 5.3          |
| Insulin-like growth factor 1 (somatomedin C); IGF1                      | A1972496                   | 5.1          |
| Syndecan 2 (heparan sulfate proteoglycan 1); SDC2                       | AL577322                   | 4.4          |
| Integrin, beta 5; ITGB5                                                  | BE138575                   | 3.7          |
| S100 calcium binding protein A4 (calcium protein, calvasculin, metastasin, murine placental homolog); S100A4 | NM_002961                  | −2.8         |
| Chondroitin sulfate proteoglycan 2 (versican); CSPG2                     | BF590263                   | −3.2         |
| Peptidyl arginine deiminase, type IV; PADI4                             | NM_012387                  | −5.9         |

**Cell cycle related**

| Glycoprotein (transmembrane) nmb; GPNMB                                    | NM_002510                  | 54           |
| Ribonucleotide reductase M2 polypeptide; RRM2                            | BC001886                   | 38           |
| Thymidylate synthetase; TYMS                                              | NM_001071                  | 7.1          |
| Ankyrin repeat domain 25; ANKRD25                                       | NM_015493                  | 5.5          |
| Deafness, autosomal dominant 5; DFNA5                                     | NM_004403                  | 5.0          |
| CDC20 cell division cycle 20 homolog (S. cerevisiae); CDC20             | NM_001255                  | 4.6          |
| JKA0101                                                                  | NM_014736                  | 3.8          |
| Enolase superfamily member 1; ENOSF1                                     | NM_017512                  | 3.7          |
| Pituitary tumor-transforming 1; PTTG1                                     | NM_004219                  | 3.4          |
| MCM2 minichromosome maintenance deficient 2, mitotin (S. cerevisiae); MCM2 | NM_004526                  | 3.2          |
| Epithelial membrane protein 1; EMP1                                       | NM_011423                  | 3.1          |
| MCM6 minichromosome maintenance deficient 6 (MSS homolog, S. pombe); MCM6 | NM_005915                  | 3.0          |
| Hypothetical protein MAC30; MAC30                                         | BF038366                   | 2.8          |
| Sprouty homolog 2 (Drosophila); SPRY2                                    | NM_005842                  | 2.8          |
| Ribonuclease, RNase A family, 1 (pancreatic); RNASE1                     | NM_002933                  | 2.8          |
| Stathmin 1; oncoprotein 18; STMN1                                         | NM_005563                  | 2.7          |
| Cyclin D3; CCND3                                                          | NM_001760                  | −2.9         |
| Ras association (RagDS/AF-6) domain family 2; RASSF2                     | NM_014737                  | −2.9         |
| Chromosome 11 open reading frame 21; C11orf21                            | NM_014144                  | −3.0         |
| Cytidylate deaminase; CDA                                                 | NM_001785                  | −4.4         |

**Cell metabolism/transport**

| Selenoprotein P, plasma; 1; SEPP1                                        | NM_005410                  | 73           |
| Apollipoprotein E; EAPOE                                                | NM_000041                  | 43           |
| Phospholipid transfer protein; PLTP                                     | NM_006227                  | 30           |
| Solute carrier organic anion transporter family, member 2B1; SLC02B1     | NM_007256                  | 21           |
| Folate receptor 2 (fetal); FOLR2                                       | NM_000803                  | 12           |
| Phosphatidic acid phosphatase type 2; PPAP2B                             | AA628586                   | 11           |
| Ectonucleotide pyrophosphatase/phosphodiesterase 2; ENPP2               | D45421                     | 10           |
| Phosphatidic acid phosphatase type 2; PPAP2A                             | AF014403                   | 7.5          |
| Dehydrogenase/reductase (SDR family); member 3; DHR53                  | NM_004753                  | 6.5          |
| Solute carrier family 2 (facilitated glucose transporter), member 1; SLC2A1 | NM_006516                  | 4.2          |
| ATP-binding cassette, sub-family A (ABC1), member 1; ABCA1              | NM_005502                  | 3.6          |
| Chromosome 9 open reading frame 95; Nicotinamide riboside kinase; C9orf95; NRK1 | NM_017881                  | 2.8          |
| Hexokinase 3 (white cell); HK3                                           | NM_002115                  | −2.7         |
| Purinergic receptor P2X, ligand-gated ion channel, 1; P2RX1              | U45448                     | −2.7         |
| RAB11 family interacting protein 1 (class I); RAB11FIP                   | NM_025151                  | −3.2         |
| MOCO sulphatase C- domain containing 1; MOSC1                           | NM_022746                  | −3.5         |
| Solute carrier organic anion transporter family, member 3A1; SLC03A1     | NM_013272                  | −3.5         |
| RAB27A, member RAS oncogene family; RAB27A                               | U38654                     | −4.0         |
| Selenoprotein X, 1; SEPX1                                               | NM_016332                  | −4.0         |
| Transketolase (Wernicke-Korsakoff syndrome); TKT                        | L12711                     | −4.0         |

*Fold change is the factor of regulation of mRNA from CD14+ cells in decidua versus CD14+ cells in blood. Positive values denote up-regulation and negative values mean down-regulation. Genes included in this table were up- or down-regulated by a factor of at least 2 in all seven subjects.

doi:10.1371/journal.pone.0002078.t003
Figure 1 shows a cluster picture of the gene signature of 408 regulated genes. Real-time PCR for confirmation of mRNA expression

Real-time PCR was used to further confirm the expression of three genes differentially expressed in the array, triggering receptor expressed on myeloid cells (TREM-2), CD209 and ICAM-3. Further, two genes, indoleamine 2,3-dioxygenase (IDO) and neuropilin (NRP-1), with two-fold regulation in all seven subjects but just below statistical significance were analyzed. PCR results showed that these five genes were differently regulated in decidual CD14 positive cells compared to cells from blood (Figure 2).

Luminex and ELISA for confirmation of protein secretion

Altered gene expression observed in the array analysis was also studied at the protein level by assaying 24-hour cell culture supernatant of CD14 positive macrophages. Decidual CD14 positive cells secreted significantly higher levels of CCL-18, CCL2 and MMP-9 compared to blood monocytes/macrophages, in agreement with the array data (Figure 3).

**Discussion**

The maternal-fetal interface presents a unique immune site with the decidua populated with numerous and specialized NK cells and macrophages. Here we report a distinct and well characterized micro-array analysis of human decidual macrophage gene expression, comprising immunomodulatory and tissue remodelling genes, as well as genes related to cell proliferation and metabolism. While only few up-regulated genes were signature of classically activated M1 macrophage phenotype [22–24], several of the regulated genes corresponded to markers of alternatively activated macrophages, including CCL18 [25], CD209 [26], mannose receptor C type (MRC)-1 [3], fibronectin-1 [3] and insulin-like growth factor (IGF)-1 [25]. All of these were recently shown to be up-regulated in blood derived M2 macrophages in a gene expression comparison with M1 polarized macrophages [22]. In addition, a number of the differentially regulated genes have previously been assigned to decidual macrophages and are confirmed by our data. We also report evidence of other markers connected to alternative macrophage activation, e.g. TREM-2, alpha 2 macroglobulin (A2M) and prostaglandin D2 synthase (PGDS).

Among the up-regulated genes a major group could be classified as immune modulatory with immuno-suppressive or anti-inflammatory functions. In agreement with this, a group of activating or pro-inflammatory genes were down-regulated in decidual macrophages compared to their blood counterparts. Several of the up-regulated genes are surface receptors, among these the often co-expressed lectins MRC-1 (CD206, macrophage mannose receptor; MMR) and CD209 as well as the tetraspanin CD9. All have previously been detected in uterine cells in human pregnancy [1,27–31]. MRC1 and CD209 (dendritic cell specific intercellular adhesion molecule-grabbing nonintegrin; DC-SIGN) are generally associated with alternative activation profile of macrophages. NRP-1, involved in establishment of the immunological synapse, is a receptor connected to regulatory T cells [32]. NRP-1 is up-regulated in decidual macrophages and was recently shown to be
up-regulated in M2 cells [22], indicating a potential role in macrophage polarization.

TREM-2 expression, to our knowledge, has not been previously reported in uterine tissue or in relation to pregnancy. In this regard, we propose a novel mechanism of potential importance of TREM-2 in maternal-fetal tolerance. In mouse macrophages, TREM-2 is induced by IL-4 and is down-regulated by IFN-γ or LPS [33]. Information on TREM-2 in humans is very limited, although it was found to be down-regulated in LPS-stimulated human monocyte-derived dendritic cells (DCs) [34]. Murine macrophages express a ligand for TREM-2 on their surface thus enabling auto-regulation [35]. High expression of TREM-2 in mouse microglial cells correlate with their ability to phagocytose apoptotic neurons, hence TREM-2 might be positively regulating phagocytosis but negatively regulating inflammatory responses [36]. This proposed dual function of TREM-2 positive cells would fit well in the context of the pregnant uterus, where the need for both immune regulation and apoptotic clearance is high.

Chemokines play a central role in polarization of macrophages. CCL2 and CCL18 were found to be up-regulated, the latter being involved in recruitment and possibly tolerance induction of naïve T cells [37]. Interestingly, CCL18 was found to be expressed in human decidual and amnion tissues during pregnancy whereas expression was reduced after onset of labour [38]. On the other hand, CCL2 (monocyte chemoattractant protein-1; MCP-1) is classically linked with inflammatory responses (reviewed in [39]). However, CCL2 was shown to drive Th2 polarization in mice and stimulation with IL-4/IL-13 in human lung epithelial cells increased their secretion of CCL2 [40]. Daly et al hypothesized a dual effect of CCL2 depending on environmental demands [39]. We therefore suggest a role for CCL2 in pregnancy in recruiting monocytes/macrophages to the decidua, where other local factors will be decisive for polarization. PGDS is another up-regulated soluble immunemodulating molecule that has been associated with decidual Th2 cell recruitment and antigen presentation [41]. IDO, a tryptophan depleting enzyme, was ascribed a role in murine pregnancy [42]. Although the role of IDO at the maternal-fetal interface has been questioned [43], its expression in decidual macrophages has previously been noted [19], thus a finding confirmed in this study.

Considering the plasticity and growth of the feto-placental unit, functions related to angiogenesis and depletion of apoptotic cells are important for a successful pregnancy. Accordingly, a large group of genes up-regulated in decidual CD14 positive cells was associated with tissue remodelling. Fibronectin increases apoptotic clearance of cells coated e.g. with C1Qs, both molecules being up-regulated here. We also found up-regulation of collagen genes as well as of other molecules promoting clearance or angiogenesis, e.g. growth arrest-specific (GAS)-6 and protein S alpha (PROS1). Although MMP9 (plasminogen) is considered a proinflammatory chemokine, it also cleaves denatured collagens and type IV collagens in basement membranes, thereby contributing to remodelling of extracellular matrix and migration of immune cells. A2M regulates functions of cytokines but in pregnancy it is suggested to particularly be involved in tissue remodelling during trophoblast invasion [44,45]. IGf-1 is an angiogenic factor that affects fetal nutrition and size (reviewed in [46]) and its expression is associated with alternatively activated macrophages [22,47], in agreement with the angiogenic characteristics of this cell type. We here confirm the role of uterine macrophages in tissue remodelling and angiogenesis during placental invasion [6,48], and extend knowledge by adding a number of regulated genes involved in tissue remodelling.

![Figure 3. Protein concentrations of a) CCL18 as measured with ELISA, b) CCL2 and c) MMP9 as measured by Luminex multiple bead technology in 24 hour culture supernatant of CD14 positive monocytes/macrophages isolated from 5 subjects. Error bars show median values and p<0.01 for differences between decidual and blood CD14 positive cells for all proteins, using Wilcoxon signed ranked test. doi:10.1371/journal.pone.0002078.g003](image-url)
A large group of regulated genes was related to cell cycle functions. Taking into consideration the balance between up- and down-regulated genes, the net effect was a clear-cut signature of proliferation, which is in line with the previously demonstrated proliferative capacity of macrophages [49,50]. Our results also closely resemble the array data from Martinez et al. [22] where many genes associated with cell proliferation were up-regulated in macrophage differentiation and priming of M1 as well of M2. Genes related to cell metabolism and transport were common both in the up- and down-regulated groups of genes. This is in line with Martinez et al where for example lipid metabolites and solute carriers were regulated in differentiation and priming of macrophages [22].

While the present study focused on analysis of the gene expression profile, previous studies have reported cell surface expression of CD14+ decidual macrophages to include CD209 [29,30], HLA-DR [19,29] and CD68 [19], whereas the relative expression of CD80, CD83 and CD86 was lowered [19,29], indicating a potential to induce T-cell anergy. Previous studies have also shown a suppression of mixed leukocyte reaction (MLR) as well as of mitogen-induced proliferation of decidual macrophages as compared with their blood counterparts, thus linking decidual macrophages to a functional suppressive phenotype [21].

Macrophages show a high degree of plasticity and they adapt to the tissue environment [51], often developing properties that do not precisely fit into the in vitro generated M1 or M2 profiles, e.g. macrophages in lung tissue [52] or in tumors (reviewed in [53]). Although decidual macrophages mainly fall into the M2 category, it is important to note that they do exhibit a unique profile. The precise requirements for this polarization remain to be settled, but local cytokines and hormones are likely to have important roles. We also speculate for a role of hepatocyte growth factor (HGF) since the gene expression profile of monocytes cultured with HGF [54] resembled that of decidual CD14 positive cells reported here. HGF is normally expressed at high levels in the placenta whereas low levels are associated with pregnancy complications [55–57]. Polarized macrophages do not represent stable lineages, but rather show reversible adaptations to changes of the environment [51,52,58]. Thus, while the unique profile of decidual macrophages is important in fetal protection, an alteration of this gene expression could be, in part, involved in complications of pregnancy. Indeed, a number of genes regulated in this array were previously found to be associated with pregnancy complications [55–57].

Purification of cell populations is extremely important in gene expression profiling. Our strategy of using gene expression in the highly purified samples as a requirement for further consideration resulted in high-stringent criteria minimizing the risk of reporting contaminating genes. The distinction between macrophages and dendritic cells in the decidua is not clear-cut. Dendritic cells may express the macrophage related CD14 [30] whereas macrophages may express the DC related CD209. [29,30]. On the other hand, CD14+ decidual cells were shown to express HLA-DR, CD68 and CD209, but were negative in CD1a, CD83 and CD86 [29] and, in addition, CD14+ cells were not able to differentiate into DCs when cultured in GM-CSF and IL-4 [19], thus indicating that CD14+ decidual cells mainly resemble macrophages. In any case, the expression profile of the major population of CD14 cells is of relevance irrespective of its relation to dendritic cells.

In conclusion, we present here the global gene expression pattern of decidual CD14 positive macrophages. The up-regulation of cell cycle genes indicates a highly proliferative nature of decidual cells. Although a number of nuclear factors were regulated, compatible with the differentiation process of decidua infiltrating macrophages, the main block of the regulated genes represented membrane receptors or secreted proteins, pointing to a profound polarization. The expression profile, with a large number of regulated genes related to immunomodulation and tissue remodelling, mainly parallels that of M2 polarized macrophages, including M2 markers such as CCL18, CD209, IGF-1, MRC-1 and fibronectin-1. Further, the up-regulation of for example TREM2, A2M and PGDS provide new insights into the regulating function of macrophages in pregnancy, and several genes might also be implicated in immune tolerance in general. Interestingly, some of the regulated genes described here for normal pregnancies, have been shown to be dysregulated in complicated pregnancies. Taken together, the mapping of decidua CD14 positive macrophages showed a unique transcriptional profile that confirms and extends previous knowledge about these cells as important components of fetal protection.

Supporting Information

Table S1 Genes differentially expressed in decidua compared to blood CD14 positive cells in early pregnancy.  
Found at: doi:10.1371/journal.pone.0002078.s001 (0.12 MB DOC)

Acknowledgments

We thank the Department of Obstetrics and Gynecology for help with collecting samples for the study, Jan-Ingvard Jonsson and Florence Sjögren for invaluable advice in the FACS/Aria cell sorting and Karin Backtman for help with flow cytometry analyses. We also want to thank Tanja Töpfer for performing the array analyses, Kåri Diemus for real-time PCR, Martina Sandberg and Maria Jennmalm for ELISA analyses, Petra Cassel for Luminex analyses and Olle Stähle for helpful input on the gene data.

Author Contributions

Conceived and designed the experiments: CG JM AM LM GB JE. Performed the experiments: RG CG JM AM. Analyzed the data: RG SS CG JM AM JE. Contributed reagents/materials/analysis tools: RG JB CG JM AM LM GB JE. Wrote the paper: CG. Other: Revision of manuscript: LM GB SS JB RG. Drafting of the manuscript: JE AM JM.

References

1. Koopman LA, Kopcow HD, Rybalow B, Boyson JE, Orange JS, et al. (2003) Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med 198: 1201–1212.
2. Stein M, Keshav S, Harris N, Gordon S (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176: 287–292.
3. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23–35.
4. Goessl S, Orfanoz CI (1999) Other functions, other genes: alternative activation of antigen-presenting cells. Immunol 10: 157–142.
5. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 675–686.
6. Mor G, Abrahams VM (2003) Potential role of macrophages as immunoregulators of pregnancy. Reprod Biol Endocrinol 1: 119.
7. Chaouat G, Cayol V, Mairovitz V, Dubanchet S (1999) Localization of the Th2 cytokines IL-3, IL-4, IL-10 at the fetomaternal interface during human and murine pregnancy and lack of requirement for Fox/Fox ligand interaction for a successful allogeneic pregnancy. Am J Reprod Immunol 42: 1–13.
29. Soilleux EJ, Morris LS, Leslie G, Chehimi J, Luo Q, et al. (2002) Constitutive cytokine secretion in decidual mononuclear cells from term human pregnancy, with or without labour: ELISPOT detection of IFN-gamma, IL-4, IL-10, TGF-beta and TNF-alpha. J Reprod Immunol 41: 31–36.

30. Deherty GB, Clark DE, Sharkey A, Sharkey SF, Smith SM (1998) Expression and function of the T-helper type-1 cytokine interleukin-12 and its receptor in the placenta during human pregnancy. Am J Reprod Immunol 39: 280–290.

31. Syrjanen J, Mottonen M, Komil J, Alanen A, Lasila O (2003) Phenotypic characterization of human term placenta. Immunology 108: 305–307.

32. Hunt JS, Pollard JW (1992) Macrophages in the uterus and placenta. Curr Top Microbiol Immunol 164: 5721–5728.

33. Mues B, Langer D, Zawadlo G, Sorg C (1989) Phenotypic characterization of human term placenta. Immunology 67: 305–307.

34. Clark DA, Keil A, Chen Z, Markert U, Manuel J, et al. (2003) Placental syncytial cell: involvement of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Jun NH2-terminal kinase 1/2 signalling pathways. Clin Exp Immunol 135: 162–172.

35. Terness P, Kallkurius M, Betz A, Rahiniova G, Saito S, et al. (2007) Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells. Am J Reprod Immunol 48: 234–247.

36. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, et al. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191–1193.

37. Brochard LS, Kennedy TG, Lala PK (1990) Suppression of lymphocyte alloreactivity by early gestational human decidua. I. Characterization of suppressor cells and suppressor molecules. J Immunol 144: 391–410.

38. Muzano A, Aoki K, Kimbara T (1994) Functions of macrophages in human decidual tissue in early pregnancy. Am J Reprod Immunol 31: 180–188.

39. Martinez FO, Gordon S, Locati M, Mantovani A (2006) Transcriptional regulation of macrophage inflammatory protein-1 alpha with a Th2-associated macrophage activation-associated CC-chemokine-1, a novel structural homologue of CCL18. J Interferon Cytokine Res 26: 619–627.

40. Kaemmerer U (2005) Antigen-presenting cells in the decidua. Chem Immunol 82: 2726–2730.

41. Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, et al. (2006) Novel insights in the regulation of CCL18 secretion by monocytes and macrophages. BMC Immunol 7: 23.

42. Aoki S, Hata T, Manabe A, Miyazaki K (1998) Decreased maternal circulating hepatocyte growth factor (HGF) concentrations in pregnancies with small for gestational age infants. Hum Reprod 13: 2950–2953.

43. Baykal C, Guler G, Ali A, Tuhunay G, Ozcer S, et al. (2005) Expression of hepatitis C virus core protein in microglial triggering receptor expressed on myeloid cells (TREM-2) and DAP12. J Immunol 177: 2051–2055.

44. Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201: 647–657.

45. van Looijen AW, van der Voort R, Le Blanc LM, Roefs MF, Schreurs BW, et al. (2006) Novel insights in the regulation of CCL10 secretion by monocytes and dendritic cells via cytokines, toll-like receptors and rheumatoid synovial fluid. BMC Immunol 7: 23.

46. Munn DH, Zhou M, Attwood JT, Dondrave I, Conway SJ, et al. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191–1193.

47. Kaemmerer U (2005) Antigen-presenting cells in the decidua. Chem Immunol 82: 2726–2730.

48. Bonanno G, Procoli A, Mariotti A, de Ritis DG, et al. (2006) Hepatitis C virus core protein enhances monocyte differentiation into regulatory interleukin (IL)-10+IL-12low/neg accessory cells with dendritic-cell features. Blood 108: 218–227.

49. Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, et al. (2006) Hepatitis C virus core protein enhances monocyte differentiation into regulatory interleukin (IL)-10+IL-12low/neg accessory cells with dendritic-cell features. Blood 108: 218–227.

50. Aoki S, Hata T, Manabe A, Miyazaki K (1998) Decreased maternal circulating hepatocyte growth factor (HGF) concentrations in pregnancies with small for gestational age infants. Hum Reprod 13: 2950–2953.

51. Baykal C, Guler G, Ali A, Tuhunay G, Ozcer S, et al. (2005) Expression of hepatitis C virus core protein in microglial triggering receptor expressed on myeloid cells (TREM-2) and DAP12. J Immunol 177: 2051–2055.

52. Aoki S, Hata T, Manabe A, Miyazaki K (1998) Decreased maternal circulating hepatocyte growth factor (HGF) concentrations in pregnancies with small for gestational age infants. Hum Reprod 13: 2950–2953.

53. Baykal C, Guler G, Ali A, Tuhunay G, Ozcer S, et al. (2005) Expression of hepatitis C virus core protein in microglial triggering receptor expressed on myeloid cells (TREM-2) and DAP12. J Immunol 177: 2051–2055.